Flagship Harbor Advisors LLC Sells 871 Shares of United Therapeutics Corporation $UTHR

Flagship Harbor Advisors LLC trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 89.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108 shares of the biotechnology company’s stock after selling 871 shares during the period. Flagship Harbor Advisors LLC’s holdings in United Therapeutics were worth $53,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. WealthCollab LLC boosted its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the period. Abich Financial Wealth Management LLC purchased a new stake in United Therapeutics during the 3rd quarter worth about $44,000. Finally, Geneos Wealth Management Inc. lifted its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on UTHR shares. Royal Bank Of Canada lifted their target price on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Morgan Stanley boosted their price objective on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, TD Cowen upped their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Ten research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $601.50.

United Therapeutics Stock Up 0.2%

NASDAQ:UTHR opened at $578.54 on Wednesday. The business’s 50-day moving average price is $520.74 and its two-hundred day moving average price is $487.07. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The stock has a market cap of $25.36 billion, a P/E ratio of 20.74, a PEG ratio of 1.64 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same quarter last year, the company posted $6.19 EPS. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. On average, equities research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 13th. The shares were sold at an average price of $574.88, for a total value of $5,748,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,851,434.88. The trade was a 34.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $565.87, for a total transaction of $4,696,721.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $25,561,479.64. The trade was a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 393,770 shares of company stock valued at $204,856,335 over the last three months. 10.30% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.